aTTP is also known as iTTP. The terms can be used interchangeably.
Claims are based on a clinical trial with 145 aTTP/iTTP patients, of which 72 obtained CABLIVI with plasma exchange and immunosuppressive treatment. The remaining 73 patients got placebo (injection without active medicine) with plasma exchange and immunosuppressive treatment. Both groups got either CABLIVI or placebo during daily plasma exchange therapy and for 30 days afterward. After treatment was stopped, everyone was followed by their doctor for 28 more days. Study showed that patients treated with CABLIVI achieved normal platelet count faster than patients in the placebo group. Also, 87% of CABLIVI-treated patients were free of relapses during the treatment period and for 28 days after versus 62% of patients treated with placebo.
Hear stories from real patients. Follow them on their personal journey from diagnosis to their day-to-day experiences of living with acquired/immune-mediated thrombotic thrombocytopenic purpura (aTTP/iTTP). Every patient's experience is unique and individual results may vary. These patients were compensated for their time creating these videos. Remember, your doctor is your best source of information and be sure to ask your doctor any questions you may have.
Alex, real patient. Individual results may vary.
Alex is being compensated by Sanofi.
On my second experience with aTTP/iTTP, my new doctor mentioned that there was a medication that could be helpful for me called CABLIVI.
Heather, real patient. Individual results may vary.
Heather is being compensated by Sanofi.
Even though I know a relapse is possible at any time, I'm confident in knowing that CABLIVI will be there.
Do not take CABLIVI if you've had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Do not take CABLIVI if you've had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.
aTTP=acquired thrombotic thrombocytopenic purpura; iTTP=immune-mediated thrombotic thrombocytopenic purpura; TTP=thrombotic thrombocytopenic purpura.